- Relationship between clinical outcomes and neutrophil-to-lymphocyte ratio levels in patients with advanced gastric cancer following chemotherapy.
| Variables | PR+SD (n=207) | PD (n=52) | P-values | PR (n=59) | PD+SD (n=200) | P-values | mOS (month) | P-values |
|---|---|---|---|---|---|---|---|---|
| NLR levels | ||||||||
| Pre-chemotherapy NLR >2.5 | 114 (55.1) | 29 (55.8) | 1.000 | 102 (51.0) | 41 (69.5) | 0.018* | 12.0 | 0.220 |
| Pre-chemotherapy NLR ≤2.5 | 93 (44.9) | 23 (44.2) | 98 (49.0) | 18 (30.5) | 15.0 | |||
| Post-chemotherapy NLR >2.5 | 70 (33.8) | 31 (59.6) | 0.001* | 85 (42.5) | 16 (27.1) | 0.048* | 11.0 | 0.0557 |
| Post-chemotherapy NLR ≤2.5 | 137 (66.2) | 21 (40.4) | 115 (57.5) | 43 (72.9) | 15.0 | |||
| NLR increase | 63 (30.4) | 26 50.0) | 0.013* | 76 (38.0) | 13 (22.0) | 0.034* | 13.0 | 0.531 |
| NLR decrease | 144 (69.6) | 26 50.0) | 124 (62.0) | 46 (78.0) | 15.0 | |||
| PLT levels | ||||||||
| Pre-chemotherapy PLT >300×109/L | 45 (21.7) | 13 (25.0) | 0.75 | 43 (21.5) | 15 (25.4) | 0.647 | 12.0 | 0.665 |
| Pre-chemotherapy PLT ≤300×109/L | 162 (78.3) | 39 (75.0) | 157 (78.5) | 44 (74.6) | 15.0 | |||
| Post-chemotherapy PLT >300×109/L | 22 (10.6) | 12 (23.1) | 0.032* | 29 (14.5) | 5 (8.5) | 0.324 | 11.0 | 0.867 |
| Post-chemotherapy PLT ≤300×109/L | 185 (89.4) | 40 (76.9) | 171 (85.5) | 54 (91.5) | 15.0 | |||
| PLT increase | 67 (32.4) | 18 (34.6) | 0.886 | 69 (34.5) | 16 (27.1) | 0.366 | 13.0 | 0.875 |
| PLT decrease | 140 (67.6) | 34 (65.4) | 131 (65.5) | 43 (72.9) | 15.0 | |||
Values are presented as numbers and precentages (%).
NLR: neutrophil-to-lymphocyte ratio, PLR: platelet count, PR: partial response, SD: stable disease, PD: progressive disease
↵* A p-value of <0.05 is statistically significant using Chi-square test or independent t-test.